Lung cancer in non-smokers — why it happens

Lung cancer in non-smokers is usually driven by a gene change inside the cancer cell rather than tobacco damage. The most common is an EGFR mutation, with ALK and ROS1 changes also seen. These driver mutations switch on uncontrolled cell growth and develop independently of smoking. Other recognised causes include secondhand smoke, radon gas, long-term air pollution and indoor cooking-fuel smoke, occupational exposures such as asbestos and silica, and a family history of lung cancer. In many patients more than one factor contributes, and sometimes no single cause can be identified.

Yes. While smoking is the biggest single cause of lung cancer, a significant and growing proportion of patients in India have never smoked — particularly women. Most never smoker lung cancer is adenocarcinoma, and in India around 40 to 50% of NSCLC patients carry an EGFR gene mutation that develops independently of tobacco. Non-smoking lung cancer can also be linked to secondhand smoke, radon gas, air pollution, indoor cooking-fuel smoke, occupational exposures, and family history. A lung cancer diagnosis in a non-smoker is not unusual in India, and it is not a mistake.

The leading cause is a driver gene mutation — most often EGFR, sometimes ALK or ROS1 — that arises inside a lung cell without any connection to smoking. Alongside these, established environmental causes include secondhand smoke, radon gas, fine-particle air pollution (PM2.5) from outdoor and indoor cooking-fuel smoke, occupational carcinogens such as asbestos, silica, diesel exhaust, arsenic, and chromium, and a family history of lung cancer or prior lung disease. Non smoker lung cancer causes often overlap, and identifying the gene driver is the most important step because it guides treatment.

The symptoms overlap, but the cause and biology often differ. Never smoker lung cancer is usually adenocarcinoma, tends to affect women and sometimes younger patients, and is far more likely to carry a targetable driver mutation such as EGFR, ALK, or ROS1. This matters for treatment: EGFR-mutated lung cancer responds dramatically to a daily targeted tablet and responds poorly to immunotherapy. That is why molecular testing of the biopsy is essential before treatment in non-smokers — to identify the cause and choose the most effective option.

It is more common than many people expect. In India, a significant and growing proportion of lung cancer patients are non-smokers, particularly women. A key reason is biology: EGFR mutations are found in roughly 40 to 50% of Indian NSCLC patients, compared to around 15% in Western populations, and these mutations develop independently of tobacco. Air pollution, indoor cooking-fuel smoke, and secondhand smoke are also widespread environmental contributors across both urban and rural India.

Both are recognised causes. Radon is a naturally occurring radioactive gas that can collect in poorly ventilated buildings and is an established cause of lung cancer in people who have never smoked. Long-term exposure to fine particulate air pollution (PM2.5) — from outdoor sources and indoor cooking-fuel or biomass smoke — is also a recognised risk. These environmental causes act over years and can contribute alongside, or independently of, a gene mutation. Reducing exposure where possible is a sensible step.

A gene mutation cannot be controlled, so no one can guarantee prevention. But several environmental causes can be reduced: avoid secondhand smoke, ventilate kitchens well and limit biomass cooking-fuel smoke, reduce exposure to outdoor pollution on high-pollution days, and follow workplace safety guidance around carcinogens such as asbestos and silica. Equally important is not ignoring a symptom — any cough, breathlessness, or chest pain that does not settle in 3 weeks deserves a chest evaluation, whatever your smoking history.

Because non-smoker lung cancer is so often caused by a targetable mutation, the biopsy report alone is not enough to plan treatment. Testing for EGFR, ALK, ROS1, and PD-L1 reveals the underlying cause and determines the most effective treatment. An EGFR-mutated cancer is best treated with a daily oral tablet, not chemotherapy or immunotherapy — and starting the wrong treatment first can deny a patient the more effective, better-tolerated option. At CION, molecular testing is reviewed as a standard step before any treatment is finalised for advanced NSCLC.

Yes, and it is particularly worthwhile in non-smokers. A second opinion is most valuable if treatment has been recommended without molecular testing of the biopsy, or if immunotherapy has been suggested without first confirming the patient does not have an EGFR mutation. CION offers a dedicated second opinion service, including a free written opinion, so you can understand the likely cause of the cancer and make a confident, informed decision before treatment begins.

Yes. CION Cancer Clinics evaluates and treats lung cancer in both smokers and non-smokers across Hyderabad, with a multidisciplinary team of medical, surgical, and radiation oncologists. Every case is reviewed by a tumour board, molecular testing is arranged from the biopsy as standard to identify the cause, and consultations run 45 minutes so decisions are never rushed. CION operates 35+ centres across Telangana and Andhra Pradesh and is rated 4.8/5 by over 1,000 patients on Google.